Dallas – October 06, 2026 -- Nanoscope Therapeutics will present four-year durability data from its RESTORE Phase 2b/3 trial of optogenetic therapy MCO-010 in retinitis pigmentosa at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, running October 8–13 in New Orleans.

Barcelona – October 06, 2026 -- Veeva Systems (NYSE: VEEV) said its Data Quality System (DQS) has aggregated and cleaned data for more than 1 million subjects across over 1,000 clinical studies, automating over 500,000 queries and eliminating thousands of hours of manual data reconciliation for sites and sponsors.

San Diego – October 06, 2026 -- Viking Therapeutics (NASDAQ: VKTX) has initiated Part 2 of a maintenance dosing study for VK2735, its dual GLP-1/GIP receptor agonist, testing oral tablet regimens alongside subcutaneous options to sustain weight loss after initial treatment.

Dover, Delaware – October 06, 2026 -- The Digital CMC Consortium has launched as a new industry collaboration aimed at the end-to-end digitalization of Chemistry, Manufacturing, and Controls (CMC) processes in drug development. Founding participants include Novartis, Thermo Fisher Scientific, Takeda, Rockwell Automation, Flagship's Pioneering Medicines, Stellix, ZS Associates, and QbDVision.

Lexington – October 06, 2026 -- Piramal Pharma Solutions (PPS) has opened a new microbiology laboratory at its Lexington site that more than triples existing testing space and is expected to cut testing times by up to 50%.

Leiden – – October 06, 2026 -- Qurin has launched the Qatra Genomic DNA Extraction Lab Kit (RUO), a Research Use Only product capable of processing urine volumes up to 400 mL, a full void, compared with the 40-50 mL standard in conventional laboratory workflows.

Oxford, England – October 06, 2026 -- Perspectum, an Oxford-based precision health company, has appointed Warren Cresswell as Chief Executive Officer, bringing more than 25 years of diagnostics and medical device leadership to the firm's push into liver and cardiometabolic disease imaging. The placement was executed by Slone Partners, a nationwide executive search firm serving life sciences and healthcare organizations.

Portland – October 06, 2026 -- Headlands Research - Summit Portland is marking 50 years of operation in 2026, having contributed clinical research to every FDA-approved class of Alzheimer's disease medication brought to market since 1993. The site, founded in 1976, has conducted more than 500 clinical trials in partnership with pharmaceutical companies and contract research organizations (CROs).

SEATTLE – October 05, 2026 -- Mozart Therapeutics presented three new data sets on its lead candidate MTX-101 at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), held September 28–October 2, 2026, in Milan, Italy, advancing the bispecific antibody toward a planned Phase 2a trial in Stage 3 type 1 diabetes with enrollment targeted for the first half of 2027.

San Rafael, Calif. – October 05, 2026 -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) appointed Cara Bauer, Ph.D., as Executive Vice President, Chief People Officer, effective Oct. 5, 2026, succeeding Amy Wireman, who is retiring after nearly 14 years at the company.